<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Treatment Response Prediction &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/treatment-response-prediction/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 06 Jan 2026 07:10:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Treatment Response Prediction &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Organoids Forecast Chemotherapy, PARP Inhibitor Outcomes in Ovarian Cancer</title>
		<link>https://bioengineer.org/organoids-forecast-chemotherapy-parp-inhibitor-outcomes-in-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 06 Jan 2026 07:09:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[organoid technology]]></category>
		<category><![CDATA[Ovarian cancer]]></category>
		<category><![CDATA[PARP inhibitors]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[Treatment Response Prediction]]></category>
		<guid isPermaLink="false">https://bioengineer.org/organoids-forecast-chemotherapy-parp-inhibitor-outcomes-in-ovarian-cancer/</guid>

					<description><![CDATA[In a groundbreaking study that could reshape the treatment landscape for advanced ovarian cancer, researchers have successfully utilized patient-derived organoids as a predictive tool for chemotherapy responses and the efficacy of PARP inhibitors. This innovative approach has the potential to personalize treatment regimens, ensuring that patients receive the most effective therapies tailored specifically to their [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314049</post-id>	</item>
	</channel>
</rss>
